Articles tagged with Nanomedicine
The ALS Association granted Lauren Sciences LLC its third award for developing LAUR-301, a V-Smart Nanomedicine for ALS. LAUR-301 aims to deliver GDNF across the blood-brain barrier and induce neuro-restoration in all ALS patients.
Research by Prof. Dr. Prasad Shastri at the University of Freiburg found that cancer cell membrane stiffness affects nanoparticle internalization; increasing stiffness enhances polymer nanoparticle entry through pathways rich in cholesterol.
Researchers created a nanomedicine platform that uses near-infrared imaging to detect tumors and kill residual cancer cells using phototherapy. The platform has shown great precision and thoroughness in cancer treatment, with promising results in mouse models.
A $3 million collaboration between the University of Liverpool and Johns Hopkins University aims to develop novel, long-acting HIV medicines. The project seeks to create implantable technologies that can deliver drugs for weeks or months, potentially improving patient adherence.
Lauren Sciences LLC has received the second grant from Voices Against Brain Cancer to continue developing LAUR-401, its innovative V-Smart Nanomedicine for Glioblastoma Multiforme. The award confirms the successful development of LAUR-401 and anticipates its potential as a transformative therapeutic for brain cancer patients.
Lauren Sciences will use the grant to customize LAUR-301 with neurotrophic factor and deliver it to disease sites in central nervous system ALS mice. The company aims for LAUR-301 to enter human clinical trials and become a transformative V-Smart TM Nanomedicine for treating ALS.
The special focus issue brings together experts from various fields to discuss the past, present, and future of nanomedicine. It addresses current debates and future perspectives on nanomedical research, including social, ethical, and safety aspects.
The European Nanomedicine Characterization Laboratory (EU-NCL) aims to bring safe and efficient nanotherapeutics faster to patients. EU-NCL partners with international reference facilities to harmonize analytical protocols, providing a trans-disciplinary testing infrastructure for preclinical characterization.
V-Smart Nanomedicine for glioblastoma multiforme (GBM) will target and deliver a known chemotherapeutic across the blood brain barrier, providing an effective new treatment option. The grant supports the development of this transformative therapeutic for brain cancer patients.
A special focus issue in Nanomedicine examines the intersection of nanomedicine and regenerative medicine, showcasing advancements in nanotopography, nanofunctionalization, and stem cell research. The field of nanoregeneration has grown exponentially over the last 15 years, with potential applications in drug discovery and cell targeting.
Researchers developed targeted biodegradable nano-drones that deliver an anti-inflammatory drug to fat deposits in arteries, successfully restructuring atherosclerotic plaques to make them more stable. The treatment reduced reactive oxygen species, increased collagen, and decreased plaque necrotic core.
The FDA has approved dozens of nanodrugs without a formal definition, leading to case-by-case examination and nonbinding guidance. This complexity hinders the development of generic nanodrugs, potentially delaying price savings for patients.
Researchers found that a particle size of 50 nm is optimal for anti-cancer nanomedicines, with enhanced performance in vivo and improved tumor inhibition.
A five-year, $1.15 million grant supports Northeastern's 'CaNCURE' program, offering 75 undergraduate students hands-on research experience with leading cancer nanomedicine experts. The program aims to address cancer disparities and motivate students to pursue careers in cancer research and clinical practice.
Researchers will use radioactive labelling to track where key materials used in nanomedicines accumulate in the body. This study aims to inform regulation and development of safer nanomedicine options for chronic conditions.
Researchers developed biodegradable nanoparticles that selectively target and resolve inflammation, potentially treating atherosclerosis and neurodegenerative diseases. The nanoparticles release an inflammation-resolving peptide drug, promoting tissue repair and reducing chronic inflammation.
Combining antiangiogenesis drugs with smaller nanomedicines may enhance treatment effectiveness for certain cancers. Vascular normalization temporarily decreases tumor blood vessel diameter, improving drug penetration of smaller particles but not larger molecules.
A realistic look at nanomedicine reveals both promise and perils. While dozens of nano health care products are in use, the field also poses risks of nanoparticle toxicity and unintended interactions.
Researchers at the University of Melbourne have successfully tracked a quantum atom inside a living human cell, paving the way for new drug discovery methods. The sensor detects biological processes at a molecular level, providing critical information about drug delivery and uptake.
The Canadian Institutes of Health Research has awarded $16 million in funding for seven new research projects on regenerative medicine and nanomedicine. These studies aim to develop new therapies and approaches to treat illnesses and diseases, ultimately improving patient outcomes.
The summit explored ways to use nanotechnology in medical imaging and therapy, focusing on targeting diseases such as cancer, neurological conditions, and cardiovascular disease. Experts discussed regulatory frameworks, design considerations, and future directions for this rapidly evolving field.
The University of Texas Health Science Center at Houston's UT nanomedicine project will be tested in space as part of a nationwide competition. The experiment aims to study the diffusion of micro nanoparticles through tiny microchannels, which could aid in developing implantable devices for controlled drug release.
The University of Copenhagen has received funding to establish a new center for pharmaceutical nanotechnology and nanotoxicology, aiming to optimize delivery systems and therapeutic benefits. The center will focus on rational design of nanotechnology materials and tools to improve therapeutic benefit-to-risk ratio.
The Mattel UCLA NanoPediatrics Program will explore the future of personalized medicine for children using nanotechnology. Researchers will develop new diagnostic tools and treatments to improve health outcomes for young patients.
Researchers developed a multistage delivery system to improve injectable drug efficacy, targeting diseased cells and releasing therapeutics in a controlled manner. The system uses mesoporous silicon particles to circumvent biobarriers and deliver diagnostic agents or therapeutic agents.
Researchers at UT Health Science Center have developed a smart particle insulin release system that detects blood sugar spikes and releases insulin to counteract them. The system, which consists of a blood sugar sensing protein and liposomes loaded with insulin, stabilized blood sugar levels in animal models for up to six hours.
Purdue University has been awarded $7 million to study the use of a nanomotor, a microscopic biological machine, for diagnosing and treating diseases like cancer and AIDS. The team will adapt a viral motor to package therapeutic DNA or RNA for disease-causing cells.
The new center will apply advanced engineering techniques and life science knowledge to control molecular interactions in cells, aiming to enhance disease treatment methods. Researchers will investigate optimal drug cocktails and mapping of molecular events that trigger stem cell differentiation.
A $6.5 million nanomedicine center at Yale University aims to design, model, synthesize, and fabricate nanomedical devices based on natural and synthetic ion transporters. The center will focus on developing biobatteries for implantable devices, including an artificial retina.
Researchers are developing functional nanoparticles that can be linked to biological molecules, enabling rapid analysis of biopsy tissue from cancer patients. These nanoprobes using quantum dots can monitor the effectiveness of drug therapy and deliver controlled amounts of drugs into genetically classified tumor cells.
The Lancet calls for increased investment in nanomedicine research, citing its potential to revolutionize disease diagnosis and treatment. The field's benefits include novel means of imaging and delivery systems for drugs and gene therapies.